Spots Global Cancer Trial Database for mcrpc
Every month we try and update this database with for mcrpc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | NCT06004661 | Metastatic Cast... | AAA617 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | NCT05369000 | Metastatic Cast... | LAVA-1207 LAVA-1207 plus ... | 18 Years - | Lava Therapeutics | |
| Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics | NCT06260410 | Prostate Cancer... | Blood draw for ... | 18 Years - | Erasmus Medical Center | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | NCT06276465 | Prostatic Cance... | Darolutamide 30... Stereotactic bo... Androgen depriv... | 18 Years - | UNICANCER | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC | NCT03432949 | Metastatic Pros... | Dexamethasone p... | - | University Health Network, Toronto | |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05241613 | Metastatic Cast... | AC176 | 18 Years - | Accutar Biotechnology Inc | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | NCT05262608 | Prostate Cancer Prostate Carcin... Metastatic Cast... | Olaparib | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | NCT04647526 | Metastatic Cast... | [Lu-177]-PNT200... Abiraterone Enzalutamide | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT06217822 | Advanced Metast... Prostate Specif... | 225Ac-PSMA-Tril... Tris-POC (BAY26... 111In-PSMA-Tril... | 18 Years - | Bayer | |
| A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC). | NCT03851640 | mCRPC | HC-1119 placebo | 18 Years - | Hinova Pharmaceuticals Inc. | |
| Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol | NCT04145375 | mCRPC | ZEN003694 Enzalutamide | 18 Years - | Zenith Epigenetics | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| 177Lu-PSMA-617 Managed Access Program for mCRPC Patients | NCT04825652 | Metastatic Cast... | 177Lu-PSMA-617 PSMA-11 | 18 Years - | Advanced Accelerator Applications | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
| A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | NCT04681144 | Prostate Cancer | Radium-223-dich... | 18 Years - | Bayer | |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | NCT03706365 | Prostate Cancer | Abemaciclib Abiraterone Ace... Prednisone Placebo | 18 Years - | Eli Lilly and Company | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | NCT04833517 | Prostate Cancer... Castration Resi... Advanced Prosta... | 18 Years - | Universität des Saarlandes | ||
| EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T | NCT05521412 | Prostate Cancer Metastatic Cast... | [ 161 Tb]Tb PSM... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Towards Optimal Prescription of Chemotherapy in Prostate Cancer | NCT02512185 | Prostate Cancer | 65 Years - | University Health Network, Toronto | ||
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| 177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer | NCT06250244 | Metastatic Cast... | 177Lu-LNC1011 | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT04221542 | Prostate Cancer | AMG 509 Abiraterone Enzalutamide | 18 Years - | Amgen | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | NCT06267729 | Metastatic Pros... | AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | NCT03395197 | mCRPC | Talazoparib wit... Placebo with en... | 18 Years - | Pfizer | |
| 177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer | NCT06250244 | Metastatic Cast... | 177Lu-LNC1011 | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | NCT03565445 | Advanced Solid ... | ASP1948 nivolumab pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC | NCT03432949 | Metastatic Pros... | Dexamethasone p... | - | University Health Network, Toronto | |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC). | NCT03851640 | mCRPC | HC-1119 placebo | 18 Years - | Hinova Pharmaceuticals Inc. | |
| imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS | NCT04746300 | Metastatic Pros... | Biopsy Blood sample | 18 Years - | Radboud University Medical Center | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | NCT05340374 | Metastatic Cast... mCRPC | Cabazitaxel 177Lu-PSMA-617 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study of INKmune in Patients With mCRPC (CaRe Prostate) | NCT06056791 | Cancer Metastatic Cast... mCRPC | INKmune | 18 Years - | Inmune Bio, Inc. | |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | NCT02266745 | Advanced Solid ... CRPC mCRPC Metastatic Cast... PT-112 Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | PT-112 Injectio... | 18 Years - | Promontory Therapeutics Inc. | |
| Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT06401980 | Metastatic Cast... | Darolutamide Standard of car... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide | NCT02130947 | Metastatic Cast... | Exercise | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | NCT03903835 | Metastatic Cast... Metastatic Horm... | Enzalutamide Or... Abiraterone Ora... Carboplatin Cabazitaxel 60 ... Docetaxel Injec... Radium Chloride... Niraparib plus ... Capivasertib pl... Apalutamide Darolutamide | 18 Years - | Karolinska Institutet | |
| A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer | NCT05968599 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer | NCT02130700 | Prostate Cancer | VT-464: given o... VT-464: given o... | 18 Years - | Innocrin Pharmaceutical | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT02057666 | Prostatic Neopl... | Tasquinimod Placebo | 20 Years - | Ipsen | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | NCT06267729 | Metastatic Pros... | AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | NCT04681144 | Prostate Cancer | Radium-223-dich... | 18 Years - | Bayer | |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | NCT04717154 | Prostatic Neopl... | Ipilimumab Nivolumab | 18 Years - | Radboud University Medical Center | |
| 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | NCT04663997 | Prostate Cancer | 177Lu-PSMA-617 Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | NCT03888612 | Prostate Cancer... | ARV-110 | 18 Years - | Arvinas Inc. | |
| A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | NCT05547061 | Prostate Cancer mCRPC | Lu-177-DGUL Ga-68-NGUL | 19 Years - | Cellbion Co., Ltd. | |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | NCT04986423 | Metastatic Cast... | ZEN003694 Enzalutamide | 18 Years - | Zenith Epigenetics | |
| Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany | NCT02450812 | Prostatic Neopl... | Radium-223-dich... | 18 Years - | Bayer | |
| Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT03761225 | Metastatic Cast... | Masitinib Docetaxel Prednisone Placebo | 18 Years - | AB Science | |
| INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations | NCT06334809 | Prostate Cancer | 18 Years - | Fondazione del Piemonte per l'Oncologia | ||
| A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer | NCT03822871 | Prostate Cancer | CTT1403 CTT1057 68Ga-PSMA-11 | 18 Years - | Cancer Targeted Technology | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
| Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT03761225 | Metastatic Cast... | Masitinib Docetaxel Prednisone Placebo | 18 Years - | AB Science | |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | NCT03454451 | Non-Small Cell ... Renal Cell Canc... Colorectal Canc... Triple Negative... Cervical Cancer Ovarian Cancer Pancreatic Canc... Endometrial Can... Sarcoma Squamous Cell C... Bladder Cancer Metastatic Cast... Non-hodgkin Lym... | CPI-006 CPI-006 + cifor... CPI-006 + pembr... CPI-006 CPI-006 + cifor... CPI-006 + pembr... | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | NCT05547061 | Prostate Cancer mCRPC | Lu-177-DGUL Ga-68-NGUL | 19 Years - | Cellbion Co., Ltd. | |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT06217822 | Advanced Metast... Prostate Specif... | 225Ac-PSMA-Tril... Tris-POC (BAY26... 111In-PSMA-Tril... | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
